Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: A retrospective comparison over 6 years

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 9-17

  Alzafiri, Raed ^a   Holcroft, Christina A ^b   Malolepszy, Paula ^a   Cohen, Albert ^a   Szilagyi, Andrew ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Inflammatory bowel diseases; Infliximab

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LEG SWELLING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; RELAPSE; RETROSPECTIVE STUDY; SINUSITIS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 79952968388     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S16168     Document Type: Article

References (32)

1. Xavier RJ, Podolsky DK. Unraveling the pathogenesis of inflammatory bowl disease. Nature. 2007;448(7152):427-434.
2. Shi D, Das J, Das G. Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Res. 2006;16(1): 70-74.
3. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113(10):1490-1497.
4. Lakatos L. Immunology of inflammatory bowel diseases. Acta Physiol Hung. 2000;87(4):355-372.
5. Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with diseases activity and response to granulocytopharesis. Am J Gastroenterol. 2002;97(11): 2820-2828.
6. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32(8):913-917.
7. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumor necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34(12):1705-1709.
8. Braegger CP, Nicholls S, Murch SH, et al. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339(8785):89-91.
9. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut. 2003;52(7):998-1002.
10. Jakobovits SL, Jewell DP, Travis SPL. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmcol Ther. 2007;25(9):1055-1060.
11. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7(2):83-88.
12. Oschenskuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16(11):1167-1171.
13. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2006;25(1): 19-37.
14. Hanauer SB, Feagan BF, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359(9317):1541-1549.
15. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9): 876-885.
16. Rutgeerts P, Sandborn WJ, Feagan BF, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-2476.
17. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
18. Rudolph SJ, Weinberg DL, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci. 2008;53(4): 1033-1041.
19. Lichtenstein GR, Diamond RH, Wagner A, et al. Infliximab administration as a 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators. Gastroenterology. 2007;132(5):A146.
20. Feagan B, McDonald JW, Panaccione R, et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gastroenterology. 2008;135(1):294-295.
21. Colombel JF, Sandborn WJ, Reinish H, et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15): 1383-1395.
22. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut. 2009;58(4):492-500.
23. Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2(10):912-920.
24. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126(2):402-413.
25. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology. 2005;128(7):1805-1811.
26. Lees CD, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26(3):411-419.
27. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: Clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6(11):1212-1217.
28. Poupardin C, Lemann M, Gendre JP, et al. Efficacy of infliximab in Crohn's disease. Result of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol. 2006;30(2):247-252.
29. Teshima CW, Thompson A, Dhanoa L, et al. Long- term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol. 2009;23(5):348-352.
30. Ferrante M, Vermeire S, Konstantinatos H, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13(2):123-128.
31. Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol Clin North Am. 2001;30(1):223-241.
32. Viscido A, Habib FI, Kohn A, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Phamacol Ther. 2003;17(10):1263-1271.